DAAs with, without PIs yield similar outcomes in decompensated HCV cirrhosis
SAN DIEGO — Researchers reported similar clinical outcomes in patients with decompensated hepatitis C virus cirrhosis treated with direct-acting antivirals, with or without protease inhibitors, according to study results.“The current study reflects real world practice on PI-based DDAs where physicians may choose to initiate PI-based DAAs in view of limited treatment options besides liver transplantation, even if this is beyond the current approved indications,” Yu Jun Wong, MD, of Stanford University, said during a presentation at Digestive Disease Week 2022. “Plus,Read More